Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2017-2021

  • Published: May 2017
  • Pages: 70
  • SKU: IRTNTR13127

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

This market research study identifies Astellas Pharma, Eli Lilly, GlaxoSmithKline, and Sanofi as the leading players in the global benign prostatic hyperplasia (BPH) drugs market. A comprehensive analysis of this market is also presented by the MOA (alpha-blockers, phosphodiesterase type-5 inhibitors, 5-alpha-Reductase inhibitors, and others) and by geography (the Americas, APAC, and EMEA).

Benign prostatic hyperplasia (BPH) drugs market analysis

According to the benign prostatic hyperplasia drugs market analysis, the global BPH drugs market is expected to grow at a steady rate and post a CAGR of more than 7% during the forecast period. The growing demand for alpha-blockers will drive the prospects for the global BPH drugs market growth for the next four years.

The growing focus on improving the convenience and tolerability of drugs has resulted in the evolution of alpha-blockers therapy that is used to treat BPH by preventing the progression of disease or reversing the signs and symptoms. The growing need for relieving lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia drives the application of alpha-blockers because these blockers are highly effective and less expensive, which in turn, will boost the demand for BPH drugs. Also, to treat the symptomatic LUTS, the US Food and Drug Administration (FDA) has approved the use of terazosin, doxazosin, tamsulosin, and alfuzosin, which are the four long-acting alpha-1 blockers.

BPH drugs market trends

The advancements in early-stage diagnosis through new diagnostic methods is one of the key BPH drugs market trends that are responsible for the market’s growth. Some of the new diagnostic methods used to help in the early detection of BPH includes phi test, Progensa, 4Kscore test, TMPRSS2: ERG, and ConfirmMDX, which are proved to be more accurate than conventional methods such as prostate-specific antigen (PSA) blood test. The availability of such advanced diagnostic methods will further drive the patient pool and fuel the market’s growth.

Benign prostatic hyperplasia drugs market growth: Competitive landscape and key vendors

The BPH drugs market is characterized by the presence of many vendors, which makes the market fragmented in nature. These vendors are increasingly competing against each other based on factors such as aggressive pricing and new indications. With the growing medical need among patients suffering from BPH, several vendors are increasingly focusing on the development of effective BPH treatment solutions, which will widen the customer base and strengthen their geographical position in the market. Furthermore, many vendors are also coming up with better products by indulging themselves in continuous innovative activities through optimal resource allocation and robust research and developmental activities.

Key vendors in the BPH drugs market

  • Astellas Pharma
  • Eli Lilly
  • GlaxoSmithKline
  • Sanofi

BPH drugs market segmentation by MOA 

  • Alpha-blocker
  • Phosphodiesterase type-5 inhibitors
  • 5-alpha-Reductase inhibitors

The BPH alpha-blockers drugs segment dominated the BPH drugs market during 2016 and will continue to dominate the market from 2017 to 2021. This segment includes several alpha-blockers such as alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax), and terazosin (Hytrin). The availability of a wide range of drugs such as Astellas Pharma's Harnal and Omnic, Sanofi's Xatral, and Recordati's Urorec is the major factor that ensures its market dominance for the next few years.

BPH drugs market overview based on geography

  • Americas
  • APAC
  • EMEA

The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2021?
  • What are the key factors driving the global benign prostatic hyperplasia (BPH) drugs market?
  • What are the key market trends impacting the growth of the global benign prostatic hyperplasia (BPH) drugs market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global benign prostatic hyperplasia (BPH) drugs market?
  • What are the market opportunities and threats faced by the vendors in the global benign prostatic hyperplasia (BPH) drugs market?
  • What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
  • What are the key outcomes of the five forces analysis of the global benign prostatic hyperplasia (BPH) drugs market?

Technavio also offers customization on reports based on specific client requirement.


Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: BPH diagnostics

  • Overview

PART 06: Pipeline landscape

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Market segmentation by MOA

  • Alpha-blockers
  • 5-ARIs
  • PDE-5 inhibitors
  • Others

PART 09: Geographical segmentation

  • BPH drugs market in Americas
  • BPH drugs market in EMEA
  • BPH drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Advancements in early-stage diagnosis through new diagnostic methods
  • Growing demand for MRI and ultrasound-guided prostate biopsy procedures
  • Growing focus toward new MOA

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • Astellas Pharma
  • Eli Lilly
  • GlaxoSmithKline
  • Sanofi
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.


Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases


Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts



  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis


  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your sample now!
  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?
  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis

Certified ISO 9001 : 2015

We are ISO recognized

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Customized Report as per your Business Needs

  • Our analysts will work directly with you and understand your needs
  • Get data on specified regions or segments, competitor and Vendors
  • Data will be formatted and presented as per your requirements
  • We offer $1000 worth of FREE customization at the time of purchase

Let us help you make report more suited to your requirements.

  • Get a competitive breakdown as per your niche industry
  • Customize the data with various metrics that meet your business prerequisite
  • Understand Revenue Sources, Customers and many more
  • Details on Market Share
  • These customizations are done in a short amount of time by our analysts and industry experts
Enquire Before Buying
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>